Rate My Professor Joshua Casan

Casan's research focuses on RNA-targeting and CRISPR-based therapeutics for cancer and infectious diseases, including mRNA engineering for selective silencing of oncogenic RNA and reversal of HIV latency. Key publications include 'Principles of CRISPR-Cas13 mismatch intolerance enable selective silencing of point-mutated oncogenic RNA with single-base precision' (Science Advances, 2024), 'Efficient mRNA delivery to resting T cells to reverse HIV latency' (Nature Communications, 2025), 'Tranexamic acid versus placebo to prevent bleeding in patients with haematological malignancies and severe thrombocytopenia (TREATT)' (The Lancet Haematology, 2025), and 'Improving outcomes for patients with lymphoma: design and development of the Australian and New Zealand Lymphoma and Related Diseases Registry' (BMC Medical Research Methodology, 2022). He has received major awards such as the Emerging Researcher Fellowship from Monash Health, NHMRC Dora Lush postgraduate scholarship, RACP NHMRC JJ Billings Scholarship, Alison Street Prize in Haematology Research, Alfred Hospital Advanced Trainee Research Prize, and Rosie Lew Postgraduate award from the Peter MacCallum Foundation. Casan contributes to the field as a member of the CLL working group of the Australasian Leukaemia and Lymphoma Group and the data management committee of the Lymphoma and Related Diseases Registry.